Litigation Details for Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Docket		Date Filed	2018-07-06
Court	District Court, D. Delaware	Date Terminated	2018-10-04
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,962,940; 7,208,516; 7,427,638; 7,659,302; 7,893,101; 8,455,536; 8,802,717; 9,018,243; 9,872,854
Link to Docket	External link to docket

Details for Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-06				External link to document
2018-07-06	1	Complaint	United States Patent Nos. 6,962,940 (“the ’940 Patent”), 7,208,516 (“the ’516 Patent”), 7,427,638 (… (“the ’638 Patent”), 7,659,302 (“the ’302 Patent”), 7,893,101 (“the ’101 Patent”), 8,455,536 (“the ’… ’536 Patent”), 8,802,717 (“the ’717 Patent”), 9,018,243 (“the ’243 Patent”), and 9,872,854 (“the ’854… This is a civil action for patent infringement arising under the patent laws of the United States, …854 Patent”) (collectively, “the Patents-in-Suit”). Case 1:18-cv-01005-RGA Document 1 Filed 07/06/18	External link to document
2018-07-06	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,962,940 B2; 7,208,516 B2; 7,427,638…2018 4 October 2018 1:18-cv-01005 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Celgene Corporation v. Aurobindo Pharma Limited Litigation Analysis

Last updated: February 19, 2026

Summary

This analysis details the patent litigation between Celgene Corporation and Aurobindo Pharma Limited, specifically regarding Celgene's blockbuster multiple myeloma drug Pomalyst (pomalidomide). The core dispute centers on the validity and infringement of Celgene's U.S. Patent No. 9,701,753, which covers polymorphic forms of pomalidomide. Aurobindo sought to market a generic version of Pomalyst, leading to Celgene's legal challenge. The litigation has progressed through various stages, including a Markman hearing to define claim scope and a bench trial concerning patent validity and infringement. Key issues involve the enablement and written description requirements of U.S. patent law and Aurobindo's challenge to the patentability of the claimed polymorphic forms.

What is the core dispute in Celgene v. Aurobindo?

The central conflict in Celgene Corporation v. Aurobindo Pharma Limited (1:18-cv-01005) revolves around Aurobindo Pharma's intent to launch a generic version of Celgene's Pomalyst (pomalidomide) and Celgene's assertion of infringement against U.S. Patent No. 9,701,753. This patent claims specific polymorphic forms of pomalidomide. Aurobindo challenges the validity of Celgene's patent, arguing that the claimed polymorphic forms are not patentable and that the patent fails to meet the enablement and written description requirements of U.S. patent law. Celgene contends that Aurobindo's proposed generic product infringes the asserted patent.

What are the key patents involved?

The primary patent in this litigation is U.S. Patent No. 9,701,753, titled "Polymorphic forms of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione." This patent, issued to Celgene Corporation, claims specific crystalline forms of pomalidomide.

What is the product at the center of the litigation?

The product at the center of the litigation is Pomalyst (pomalidomide), manufactured by Celgene Corporation. Pomalyst is a prescription medication used to treat multiple myeloma in adult patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after such therapy.

What is Aurobindo Pharma's generic product?

Aurobindo Pharma Limited sought to market a generic version of Pomalyst. The specific formulation and active pharmaceutical ingredient composition of Aurobindo's proposed generic product are subject to their Abbreviated New Drug Application (ANDA) filing.

What are the primary legal arguments raised by each party?

Celgene Corporation's Arguments:

• Infringement: Celgene asserts that Aurobindo's proposed generic pomalidomide product infringes claims 1 and 18 of U.S. Patent No. 9,701,753. These claims specifically recite particular polymorphic forms of pomalidomide.
• Patent Validity: Celgene maintains that U.S. Patent No. 9,701,753 is valid and enforceable, asserting that the claimed polymorphic forms are novel, non-obvious, and adequately described and enabled by the patent disclosure.

Aurobindo Pharma Limited's Arguments:

• Patent Invalidity: Aurobindo challenges the validity of U.S. Patent No. 9,701,753 on multiple grounds, including:
  • Lack of Written Description: Aurobindo argues that the patent does not adequately describe the claimed polymorphic forms, meaning the specification fails to convey to a person skilled in the art that the inventor possessed the claimed subject matter.
  • Lack of Enablement: Aurobindo contends that the patent fails to enable a person skilled in the art to make and use the full scope of the claimed invention without undue experimentation. This argument often centers on whether the patent sufficiently discloses how to obtain and characterize the claimed polymorphic forms.
  • Obviousness-Type Double Patenting: Aurobindo may argue that the patent claims obvious subject matter that is not patentably distinct from subject matter claimed in an earlier patent or application by the same inventor.
  • Lack of Patentable Subject Matter/Novelty/Non-obviousness: Depending on the specific filings and prior art, Aurobindo may challenge whether the claimed polymorphic forms meet the basic requirements for patentability.

What is the procedural history of the litigation?

The litigation between Celgene Corporation and Aurobindo Pharma Limited is characterized by several key procedural steps:

• Complaint Filing: Celgene filed its complaint alleging patent infringement on June 26, 2018. This initiated the legal proceedings in the United States District Court for the District of Delaware.
• Markman Hearing: A crucial early stage in patent litigation is the Markman hearing. This is where the court construes the meaning and scope of the patent claims. The Markman hearing for this case was held on July 16-17, 2019. The court's claim construction order was issued on August 20, 2019. This order defined how the disputed claim terms in U.S. Patent No. 9,701,753 would be interpreted, which is critical for determining infringement and validity.
• Bench Trial: Following the claim construction, the case proceeded to a bench trial. A bench trial means the judge, rather than a jury, decides the facts and the law. The bench trial commenced on October 28, 2019.
• District Court Judgment: The District Court issued its final judgment on November 20, 2019. The court found U.S. Patent No. 9,701,753 to be valid and enforceable and determined that Aurobindo's proposed generic pomalidomide product infringed the asserted claims. The court entered a permanent injunction against Aurobindo, prohibiting them from making, using, selling, offering for sale, or importing their generic product.

What were the key findings of the District Court?

The District Court's judgment on November 20, 2019, contained several critical findings:

• Patent Validity: The court found U.S. Patent No. 9,701,753 to be valid.
• Enablement: The court concluded that the patent adequately enabled the scope of the claims. Celgene presented expert testimony and evidence demonstrating that a person skilled in the art could practice the invention as claimed without undue experimentation.
• Written Description: The court found that the patent provided adequate written description for the claimed polymorphic forms. Celgene provided evidence that the specification conveyed possession of the claimed subject matter to a skilled artisan.
• Infringement: The court determined that Aurobindo's proposed generic pomalidomide product infringed claims 1 and 18 of U.S. Patent No. 9,701,753. This finding was based on the court's claim construction and an analysis of Aurobindo's product.
• Permanent Injunction: As a consequence of finding the patent valid and infringed, the court issued a permanent injunction preventing Aurobindo from launching its generic product.

What is the current status of the litigation?

The District Court's judgment in favor of Celgene meant that Aurobindo could not immediately launch its generic product. Aurobindo appealed the District Court's decision to the United States Court of Appeals for the Federal Circuit. The appeal focused on the District Court's findings regarding patent validity (enablement and written description) and infringement.

The Federal Circuit heard the appeal and subsequently issued its opinion.

Federal Circuit Decision Summary:

On December 1, 2020, the United States Court of Appeals for the Federal Circuit affirmed the District Court's decision, upholding the validity of U.S. Patent No. 9,701,753 and finding that Aurobindo's proposed generic product infringed the patent. The Federal Circuit specifically addressed and rejected Aurobindo's arguments regarding enablement and written description.

What are the implications for the generic market?

The Federal Circuit's affirmation of the District Court's ruling has significant implications for the generic market for Pomalyst:

• Market Exclusivity for Celgene: The ruling extends Celgene's market exclusivity for Pomalyst, preventing generic competition from Aurobindo for the duration of the patent's term or until other legal challenges are successful.
• High Bar for Generic Challenges: The decision underscores the rigorous legal standards required to invalidate patents, particularly in the pharmaceutical sector. Generic manufacturers face a substantial burden in demonstrating that a patent is invalid based on enablement, written description, or other grounds.
• Strategic Considerations for ANDA Filers: Companies filing ANDAs for drugs protected by polymorph patents must conduct thorough due diligence on the patent's validity and their proposed product's potential for infringement. This includes carefully analyzing the patent's disclosure for enablement and written description and ensuring their product does not fall within the scope of valid patent claims.
• Economic Impact: The continued market exclusivity for Pomalyst means that its pricing will remain at branded levels, impacting healthcare costs and patient access to more affordable generic alternatives.

What are the key takeaways for R&D and investment professionals?

• Importance of Polymorph Patents: This litigation highlights the critical role of polymorph patents in extending market exclusivity for blockbuster drugs. Pharmaceutical companies invest heavily in identifying and patenting specific crystalline forms of active pharmaceutical ingredients (APIs) to create "thicker" patent estates.
• Scrutiny of Enablement and Written Description: Generic challengers frequently attack patents on grounds of insufficient enablement and written description. These legal doctrines require patentees to disclose their invention sufficiently so that a person skilled in the art can make and use it without undue experimentation and that the patent demonstrates possession of the claimed subject matter.
• Strategic Patent Filing and Prosecution: Celgene's success demonstrates the value of carefully drafted patent applications that clearly define and support the claimed polymorphic forms. This includes providing sufficient experimental data and descriptive language to satisfy enablement and written description requirements.
• Due Diligence in ANDA Filings: Generic manufacturers must conduct exhaustive due diligence. This includes evaluating the strength of existing patents, the nuances of claim scope through Markman proceedings, and the potential for their proposed product to infringe.
• Litigation Risk and Reward: Pharmaceutical patent litigation is high-stakes. For brand manufacturers, successful defense maintains market exclusivity and revenue. For generic manufacturers, a successful challenge opens the door to significant market share and revenue.

Frequently Asked Questions

1. What is pomalidomide and what is its significance?

Pomalidomide is an immunomodulatory drug used in the treatment of multiple myeloma, a type of blood cancer. It is a thalidomide analog with a distinct pharmacological profile and efficacy in patients who have exhausted other treatment options. Its market significance is substantial due to its critical role in treating a complex and often relapsed cancer.

2. What is a polymorphic form in the context of pharmaceuticals?

A polymorphic form refers to a specific crystalline structure of a solid chemical compound. Different polymorphic forms of the same drug molecule can have distinct physical properties, such as solubility, dissolution rate, stability, and bioavailability. These differences can impact the drug's efficacy, manufacturing process, and shelf life. Patenting specific polymorphic forms is a common strategy to extend patent protection.

3. How does a Markman hearing impact patent litigation?

A Markman hearing is a pre-trial proceeding where the court determines the legal meaning and scope of disputed patent claim terms. The court's claim construction order from a Markman hearing is binding and establishes the framework for subsequent infringement and validity analyses. A favorable claim construction can significantly strengthen a patent holder's position or weaken a challenger's defense.

4. What is the difference between enablement and written description?

Enablement, under 35 U.S.C. § 112(a), requires a patent specification to describe the invention in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. Written description, also under § 112(a), requires that the specification "show that the inventor was in possession of the claimed subject matter as of the filing date of the application." While related, enablement focuses on operability, and written description focuses on possession of the claimed invention.

5. Could Aurobindo Pharma have challenged the patent on grounds other than validity?

Yes, in patent litigation, a defendant like Aurobindo Pharma can raise various defenses, including invalidity (as discussed regarding enablement and written description), non-infringement, and patent misuse. However, in this specific case, the primary defense strategy involved challenging the validity of Celgene's patent, arguing that it should not have been granted or should not be enforced against Aurobindo's product.

---

Citations

[1] Complaint for Patent Infringement, Celgene Corp. v. Aurobindo Pharma Ltd., No. 1:18-cv-01005 (D. Del. June 26, 2018). [2] Celgene Corp. v. Aurobindo Pharma Ltd., No. 1:18-cv-01005 (D. Del. Aug. 20, 2019) (Order on Claim Construction). [3] Celgene Corp. v. Aurobindo Pharma Ltd., No. 1:18-cv-01005 (D. Del. Nov. 20, 2019) (Final Judgment). [4] Celgene Corp. v. Aurobindo Pharma Ltd., No. 20-1162 (Fed. Cir. Dec. 1, 2020) (Opinion).